Dyadic International, Inc.
NASDAQ:DYAIBiotechnology
+$0.26 today
- Market cap
- $53.56M
- Beta
- 1.15
- P/E (TTM)
- -6.9
- EPS (TTM)
- -$0.20
Volume 0.71M
Average 0.31M
DYAI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Dyadic International, Inc.NASDAQ: DYAI
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $476.07K fell 3.8% year over year, ahead of the -5.1% change in trailing-twelve-month research & development. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at -21.8% a year.
Context
- Research & development amounted to 174.8% of revenue in FY2025, up 116.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -3.8% holds above the trailing-twelve-month pace of -5.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 2.15M USD
- Year-over-year change
- +5.4%
- 4-year CAGR
- -28.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.15M | +5.4% |
| FY2024 | 2024-12-31 | 2.04M | -38.0% |
| FY2023 | 2023-12-31 | 3.3M | -26.7% |
| FY2022 | 2022-12-31 | 4.5M | -46.4% |
| FY2021 | 2021-12-31 | 8.39M | — |
Research & Development vs competitors
How DYAI compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.1% is the 4th highest of 8, against a peer median of -8.9%.
- Research & development amounts to 64.3% of revenue for DYAI, versus a peer median of 264.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.74B USD | +90463.6% | +15.1% | — | |
| LTM Mar 2026 | $23.45M USD | -1.8% | -5.3% | — | |
| LTM Dec 2025 | $15.03M USD | -13.6% | -42.3% | 56.6% | |
| LTM Mar 2026 | $14.87M USD | +36.6% | +1076.5% | — | |
| FY2025 | A$14.4M AUD | -22.7% | -0.8% | 264.8% | |
| LTM Mar 2026 | $10.43M USD | -41.5% | -39.6% | — | |
| LTM Mar 2026 | $5.84M USD | -8.9% | +13.4% | 392.2% | |
| LTM Mar 2026 | $1.91M USD | -5.1% | -21.8% | 64.3% | |
| Peer median (excluding DYAI) | — | -8.9% | -0.8% | 264.8% | |
Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.4M | 2.93M | 2.9M | 3.5M | 1.23M |
| Cost of Revenue | 1.94M | 2.12M | 1.98M | 1.19M | 2.32M |
| Gross Profit | 459.39K | 807.11K | 922.96K | 2.3M | (1.09M) |
| Gross Margin | 19.1% | 27.5% | 31.8% | 65.8% | -88.3% |
| Research & Development | 8.39M | 4.5M | 3.3M | 2.04M | 2.15M |
| Selling, General & Admin | 6.7M | 6.42M | 5.82M | 6.13M | 5.76M |
| Operating Expenses | 15.19M | 10.97M | 9.15M | 8.2M | 6.06M |
| Depreciation & Amortization | 3.49M | 0 | 38.42K | 0 | 0 |
| EBITDA | (11.14M) | (10.12M) | (8.15M) | (5.38M) | (6.91M) |
| EBITDA Margin | -463.4% | -345.2% | -281.3% | -154.0% | -560.6% |
| Operating Income | (14.73M) | (10.17M) | (8.23M) | (5.9M) | (7.15M) |
| Operating Margin | -612.7% | -346.9% | -283.9% | -168.8% | -579.9% |
| Interest Income | 51.7K | 180.42K | 416.69K | 456.99K | 284.09K |
| Interest Expense | 0 | 0 | 0 | 427.97K | 455.9K |
| Other Income / Expenses | 1.66M | 430.42K | 1.43M | 91.66K | (218.71K) |
| Income Before Tax | (13.07M) | (9.74M) | (6.8M) | (5.81M) | (7.36M) |
| Pre-Tax Margin | -543.7% | -332.2% | -234.4% | -166.2% | -597.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.07M) | (9.74M) | (6.8M) | (5.81M) | (7.36M) |
| Net Margin | -543.7% | -332.2% | -234.4% | -166.2% | -597.6% |
| EPS (Basic) | (0.47) | (0.34) | (0.24) | (0.20) | (0.23) |
| EPS (Diluted) | (0.47) | (0.34) | (0.24) | (0.20) | (0.23) |
| Weighted Avg Shares | 27.84M | 28.36M | 28.8M | 29.32M | 32.62M |
| Weighted Avg Shares (Diluted) | 27.84M | 28.36M | 28.8M | 29.32M | 32.62M |
Dyadic International, Inc.
NASDAQ:DYAI
Intrinsic Alpha fair value
Locked
Current Price
$1.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.